About Us
Healthcare Industry Expertise
Independent diligence for private equity, venture capital, startups and strategics—focused on interventional cardiology, interventional radiology, and vascular surgery technologies in CAD, PAD, venous disease, and arterial embolization. We want to help you determine which endovascular innovations will translate into procedural adoption, scalable revenue, and profitable returns.
Given many product, procedure, technologies, workflow, reimbursement and site of care variables at play, we'll help you decide where to play and how to win.
Medical Sector Strategies
Our focus is highly specialized: devices used by interventional cardiologists, interventional radiologists, and vascular surgeons, with deep domain expertise in coronary artery disease (CAD) and peripheral arterial disease (PAD), venous disease, and oncology applications—particularly liver-directed therapies.
How We Can Help
We help investors determine whether a technology will move beyond technical promise to consistent procedural adoption, reimbursement durability, and scalable revenue. This includes evaluating clinical differentiation in real-world practice, alignment with physician workflow, competitive positioning within established treatment algorithms, and the practical barriers to penetration in cath labs, IR suites, and vascular programs, in both the acute care and outpatient care settings. In short, the path to commercialization.
With US and OUS based corporate leadership pedigree, we value the importance of making the right strategic decisions supporting the plan's tactical execution.
Expert Strategic Consulting
Leveraging more than three decades of leadership in the medical device sector—and with experience in acquisition, divestiture, and building commercial teams delivering profitable growth—we advise on the true investment potential of interventional technologies.
As a single-principal firm led by Chris Pearson, Slocum Advisors delivers highly personalized engagement, while maintaining the flexibility to call in trusted functional experts determined by the project.
With a proven track record of scaling organizations from $300 million to over $1.2 billion, Chris brings an operator’s lens to diligence—identifying not just opportunity, but the friction points that often prevent interventional platforms from achieving meaningful market share.
